Healthcare Industry News: benign prostatic hyperplasia
News Release - November 8, 2007
Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent CaseTOKYO and RIDGEFIELD, Conn., Nov. 8 (HSMN NewsFeed) -- Astellas Pharma Inc. and Boehringer Ingelheim Pharmaceuticals, Inc. (a subsidiary of Boehringer Ingelheim Corporation) announced today that the two companies have reached a settlement agreement with Ranbaxy to enter into a stipulation of dismissal of the pending U.S. litigation with regard to U.S. Patent No. 4,703,063 for Flomax® (tamsulosin hydrochloride) capsules, a treatment for the signs and symptoms of benign prostatic hyperplasia (BPH).
As a result of this settlement, the case will be dismissed without prejudice. The settlement of the litigation provides Ranbaxy with the opportunity to launch a generic tamsulosin hydrochloride product on March 2, 2010, prior to the expiration of pediatric exclusivity if such is granted by the FDA. Further terms of the settlement will not be disclosed.
Source: Boehringer Ingelheim
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.